MTAP deletion

News alerts, weekly reports and conference planners

Entrez ID:

4507

Related biomarkers:

‹

MTAP mutation + CDKN2A mutation (2)

MTAP mutation (2)

MTAP mutation + CDKN2A mutation (2)

›

MTAP deletion	Non Small Cell Lung Cancer	MTAP deletion	Non Small Cell Lung Cancer	IDE397 Sensitive: C2 – Inclusion Criteria IDE397 Sensitive : C2	IDE397 Sensitive: C2 – Inclusion Criteria IDE397 Sensitive : C2
MTAP deletion	Solid Tumor	MTAP deletion	Solid Tumor	TNG908 Sensitive: C2 – Inclusion Criteria TNG908 Sensitive : C2	TNG908 Sensitive: C2 – Inclusion Criteria TNG908 Sensitive : C2
MTAP deletion	Solid Tumor	MTAP deletion	Solid Tumor	TNG462 Sensitive: C2 – Inclusion Criteria TNG462 Sensitive : C2	TNG462 Sensitive: C2 – Inclusion Criteria TNG462 Sensitive : C2
MTAP deletion	Urothelial Cancer	MTAP deletion	Urothelial Cancer	pemetrexed Sensitive: C3 – Early Trials pemetrexed Sensitive : C3	pemetrexed Sensitive: C3 – Early Trials pemetrexed Sensitive : C3
MTAP deletion	Lung Adenocarcinoma	MTAP deletion	Lung Adenocarcinoma	pemetrexed Sensitive: C3 – Early Trials pemetrexed Sensitive : C3	pemetrexed Sensitive: C3 – Early Trials pemetrexed Sensitive : C3
MTAP deletion	Squamous Cell Carcinoma of Head and Neck	MTAP deletion	Squamous Cell Carcinoma of Head and Neck	pembrolizumab + afatinib Resistant: C3 – Early Trials pembrolizumab + afatinib Resistant : C3	pembrolizumab + afatinib Resistant: C3 – Early Trials pembrolizumab + afatinib Resistant : C3
MTAP deletion	Esophageal Cancer	MTAP deletion	Esophageal Cancer	AMG 193 Sensitive: C3 – Early Trials AMG 193 Sensitive : C3	AMG 193 Sensitive: C3 – Early Trials AMG 193 Sensitive : C3
MTAP deletion	Renal Cell Carcinoma	MTAP deletion	Renal Cell Carcinoma	AMG 193 Sensitive: C3 – Early Trials AMG 193 Sensitive : C3	AMG 193 Sensitive: C3 – Early Trials AMG 193 Sensitive : C3
MTAP deletion	Gallbladder Cancer	MTAP deletion	Gallbladder Cancer	AMG 193 Sensitive: C3 – Early Trials AMG 193 Sensitive : C3	AMG 193 Sensitive: C3 – Early Trials AMG 193 Sensitive : C3
MTAP deletion	Pancreatic Cancer	MTAP deletion	Pancreatic Cancer	AMG 193 Sensitive: C3 – Early Trials AMG 193 Sensitive : C3	AMG 193 Sensitive: C3 – Early Trials AMG 193 Sensitive : C3
MTAP deletion	Ovarian Cancer	MTAP deletion	Ovarian Cancer	AMG 193 Sensitive: C3 – Early Trials AMG 193 Sensitive : C3	AMG 193 Sensitive: C3 – Early Trials AMG 193 Sensitive : C3
MTAP deletion	Gastric Cancer	MTAP deletion	Gastric Cancer	IDE397 Sensitive: D – Preclinical IDE397 Sensitive : D	IDE397 Sensitive: D – Preclinical IDE397 Sensitive : D
MTAP deletion	Esophageal Cancer	MTAP deletion	Esophageal Cancer	IDE397 Sensitive: D – Preclinical IDE397 Sensitive : D	IDE397 Sensitive: D – Preclinical IDE397 Sensitive : D
MTAP deletion	Head and Neck Cancer	MTAP deletion	Head and Neck Cancer	IDE397 Sensitive: D – Preclinical IDE397 Sensitive : D	IDE397 Sensitive: D – Preclinical IDE397 Sensitive : D
MTAP deletion	Pancreatic Cancer	MTAP deletion	Pancreatic Cancer	IDE397 Sensitive: D – Preclinical IDE397 Sensitive : D	IDE397 Sensitive: D – Preclinical IDE397 Sensitive : D
MTAP deletion	Bladder Cancer	MTAP deletion	Bladder Cancer	IDE397 Sensitive: D – Preclinical IDE397 Sensitive : D	IDE397 Sensitive: D – Preclinical IDE397 Sensitive : D
MTAP deletion	Colorectal Cancer	MTAP deletion	Colorectal Cancer	MRTX9768 Sensitive: D – Preclinical MRTX9768 Sensitive : D	MRTX9768 Sensitive: D – Preclinical MRTX9768 Sensitive : D
MTAP deletion	Solid Tumor	MTAP deletion	Solid Tumor	BMS‐986504 Sensitive: D – Preclinical BMS‐986504 Sensitive : D	BMS‐986504 Sensitive: D – Preclinical BMS‐986504 Sensitive : D
MTAP deletion	Lung Adenocarcinoma	MTAP deletion	Lung Adenocarcinoma	IDE397 Sensitive: D – Preclinical IDE397 Sensitive : D	IDE397 Sensitive: D – Preclinical IDE397 Sensitive : D
MTAP deletion	Glioblastoma	MTAP deletion	Glioblastoma	TNG908 Sensitive: D – Preclinical TNG908 Sensitive : D	TNG908 Sensitive: D – Preclinical TNG908 Sensitive : D

MTAP deletion

Associations